Pharmaceutical Development

Morphic is developing a so-called selective oral small molecule inhibitor for the treatment of inflammatory bowel disease.

July 8, 2024

Private equity firms are creating clinical trial platforms to roll up independents in a highly fragmented industry.

January 9, 2024

RayzeBio targets a variety of tumors in the lungs, pancreas, liver and other organs with radioactive drugs,

December 26, 2023

The deal officially ends STADA’s previously planned IPO and is expected to close in early 2026, pending regulatory and closing conditions.

September 2, 2025

Merck is under pressure to pursue M&A amid declining Keytruda revenue.

June 3, 2025

The therapy, known as NM26, targets two proteins that cause the itchiness and inflammation of eczema.

May 28, 2024

The company manufactures and distributes over-the-counter pharmaceutical dermatological preparations.

March 1, 2024

The deal enhances Catalent's integrated oral solid formulation development, manufacturing and packaging.

August 11, 2022

Trending